Overview
Alveolus Bio has raised $2M in a Seed round on Jul 1, 2025, with participation from Shilpa Medicare. The company pioneering biotherapeutic delivery. The round will be used to accelerate product development, expand the team, and scale go-to-market operations.
Operating in the biotechnology research sector, Alveolus Bio is positioned to capitalize on growing demand for innovative solutions in this space. With fresh capital, the company is expected to invest heavily in R&D and talent acquisition, signaling a period of aggressive growth ahead.
Market Outlook
This funding positions Alveolus Bio as one to watch in the biotechnology research landscape. As the company scales, it will likely become an increasingly attractive partner — and customer — for B2B vendors looking to sell into well-funded, growth-stage companies. The post-raise window of 60-90 days is typically when startups are most receptive to new tools, services, and partnerships.
Why contact Alveolus Bio now
Alveolus Bio just closed $2M in Seed funding — which means they're actively scaling their team, upgrading their tech stack, and looking for vendors who can help them move fast. Companies at this stage typically make purchasing decisions within 60-90 days of closing a round. If you sell to biotechnology research companies, this is your window to reach out before competitors do.
Founders & Contacts
Investors
Company Facts
| Company | Alveolus Bio |
| Amount Raised | $2M |
| Funding Round | Seed |
| Date Raised | Jul 1, 2025 |
| Founded | 2022 |
| Industry | Biotechnology Research |
| Founders |
Get Verified Founder Emails
Access verified email addresses and contact details for Alveolus Bio's founders and thousands of other funded startups.
Start Free Trial